aβ peptides

Ganglioside GM1-binding peptide sp3 is a synthetically engineered peptide that specifically binds to the pentasaccharide region of GM1 ganglioside. The dynamic transitions of Ganglioside GM1-binding peptide sp3 may play a crucial role in the functions of GM1 as a receptor for various ligands, such as in the conventional pathway of cholera toxin infection. This peptide is useful for studies on the interactions between GM1 and its ligands.

Edonerpic maleate (T-817 maleate) is a neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

MRK-560 is an effective and brain-penetrant inhibitor of γ-secretase.

BuChE-IN-20 is a selective hBuChE inhibitor (IC50= 0.13 μM) with the ability to cross the blood-brain barrier (BBB). This compound, a derivative of L-Tryptophan, exhibits neuroprotective effects by inhibiting nitric oxide (NO) production and reducing reactive oxygen species (ROS) levels. It effectively suppresses the self-aggregation of amyloid-beta (Aβ) peptides and is applicable in Alzheimer's disease research.

BChE-IN-31 (Compound 14d) is a selective butyrylcholinesterase inhibitor with an IC50 value of 65 nM. It effectively inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptides.

BSBM6 is an inhibitor of Aβ aggregation and neuronal toxicity that acts by reversing the aggregation and toxicity of amyloid-β peptides.

Elenbecestat,also known as E2609 is a BACE1 inhibitor. By inhibiting BACE, a key enzyme in the production of Aβ peptides, E2609 decreases the formation of these peptides which can aggregate into toxic oligomers and protofibrils and eventually form amyloid plaques in the brain. Elenbecestat has been shown to reduce Aβ levels in cerebrospinal fluid, was investigated in two global phase 3 studies in early AD.

Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and functions as an efficient, non-competitive, long-acting, and selective inhibitor of acetylcholinesterase (AChE). This compound reduces the formation of amyloid precursor protein (APP) and β-amyloid peptides (Aβ), potentially improving cognitive abilities and alleviating the progression of Alzheimers disease.

Anti-BACE1 Antibody is a humanized monoclonal antibody targeting beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 is a transmembrane aspartic protease and the rate-limiting enzyme for the generation of Aβ peptides in Alzheimer's disease (AD). This antibody functions by specifically binding to the extracellular domain of BACE1, neutralizing its enzymatic activity or inducing receptor internalization to block the beta-site cleavage of amyloid precursor protein (APP). This process effectively reduces the production of toxic Aβ40/42 and inhibits the formation and deposition of amyloid plaques, making it a pivotal tool for researching the pathogenesis and immunotherapeutic strategies of neurodegenerative diseases.

PF-04382923 is a humanized IgG2Δa monoclonal antibody. It binds with high affinity to the free C-terminal region of amyloid β (Aβ) peptides Aβ1-40 and Aβ1-42. PF-04382923 is utilized in research concerning geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD).

MEDI-1814 is a fully human IgG1 antibody targeting the C-terminus of Aβ42. It binds to and eliminates circulating Aβ peptides, thereby preventing their aggregation into toxic oligomers. MEDI-1814 is applicable in Alzheimer's disease research. For an isotype control, refer to HumanIgG1kappa, Isotype Control.